Opioid-based Versus Opioid-free Anaesthesia for Laparoscopic Cholecystectomy

Not Applicable

Completed

• Conditions: Surgical Procedure, Unspecified; Laparoscopic Cholecystectomy
• Interventions: Drug: Dexmedetomidine injection; Drug: Nalbuphine Injection

• Registration Number: NCT06476600
• Lead Sponsor: Atif Shafqat

Brief Summary

This is a prospective, randomized, parallel-group, double-blinded clinical trial. The study is approved by the DUHS institutional review board (IRB) and the trial will be registered at clinical trial registry. The participants of the study will be invited once they receive full trial information from the surgeons or the anesthetists during their pre-assessment visits. The study participants will join only for up to one day after the surgery (Post-operative day-1). The intervention consists of administration of dexmedetomidine infusion in opioid free anesthesia (OFA) group versus Nalbuphine IV bolus in opioid-based anesthesia (OA) group, five minutes before induction of anesthesia. For maintenance in OFA group dexmedetomidine infusion is to be continued whereas in OA group Nalbuphine IV bolus doses will be administered. Once the surgery is completed and after extubation and emergence from anesthesia, all the participants will be transferred to PACU from where they will be in turn discharged to the ward once they will fulfil the recovery discharge criteria. A multi-modal analgesia regimen along with a prophylactic antiemetic medication will be prescribed postoperatively to all the patients in the ward according to the standard protocol of the department.

Detailed Description

Opioid-based (OA) Versus Opioid-free Anaesthesia (OFA) for General Surgical procedures in a developing country.

Introduction:

Opioids and their synthetic derivatives were first used in anesthesia in 1962. They are now routinely dispensed via different routes of administration including oral, subcutaneous, intravenous, intramuscular, transdermal, epidural or intrathecal. In the last 20 years, the world has witnessed a substantial increase in the consumption of opioids. Opioids over prescription is one of the causative factors of opioid crisis in North America. The current global opioid crisis has multifactorial reasons, and this is gradually worsened due to the different waves of liberal opioid use. The ongoing opioid crisis has led to the development of alternative techniques like opioid sparing and opioid-free anaesthesia strategies. Owing to the well-researched and recognized opioid-based anaesthesia adverse effects, it is essential to develop alternative therapies to achieve the main benefits of opioids like analgesia and haemodynamic stability, while limiting the opioid related adverse effects. A sensible use of opioids in the perioperative period is important since vulnerable patients undergoing common general surgical procedures become chronic opioid users postoperatively. High doses of perioperative opioids can be associated with increased post-operative complications including respiratory depression, paralytic ileus, nausea and vomiting, difficulty voiding, pruritus, hyperalgesia and opioid tolerance. These can atypically increases the length of hospital stay (LOS) due to delayed patient recovery, prolonged PACU stay, delayed discharge and unanticipated hospitalization; thus overall compromising the quality of recovery (QoR) and putting unnecessary burden on both the patients' and hospital resources.

Opioid-free anesthesia(OFA) is a method that entirely eliminates the use of systemic, neuraxial, or intracavitary opioids. A less restrictive practice is opioid-sparing anesthesia (OSA), where small amounts of opioids are used. Patients suffering from chronic postsurgical pain, complex regional pain syndrome, cancer-related pain, and other opioid-tolerant patients may also benefit from OFA and OSA approaches.

OFA involves multimodal non-opioid analgesia, which uses sympatholytic drugs and non-opioid analgesics. These drugs can reduce or avoid the use of opioids in the postoperative period. A non-opioid multimodal analgesic method is intended at enhancing adjunctive options that is applying anesthetic techniques aiming different neuro-anatomical circuits and several neurophysiological mechanisms. Non-opioid analgesics include: alpha-2agonists (clonidine and dexmedetomidine), beta-blockers (esmolol), gabapentinoids (gabapentinand pregabalin), lidocaine (lidocaine hydrochloride), magnesium (magnesium sulfate), ketamine and dexamethasone. These drugs when used in combination acts synergistically and change the pathophysiology of nociception thus causes effective analgesia with minimal side effects.

OFA is an efficacious mode of anaesthetic for general surgical procedures when compared to conventional opioid-based anaesthesia (OA). However, the evidence on OFA is still debatable. Therefore there is still a feasibility issue of OFA for common general surgical procedures, which needed to be established.

The quality of recovery after anaesthesia and surgery does not only include pain control but it also involves patient's overall generalised health status in the postoperative period including return of self-care, household and work activities, and mobility compared to preoperative period. Patient-reported outcome measures (PROMs) are considered as the benchmark tools for measuring global health state and post-surgical recovery after any procedure. The QoR-15 is a validated PROM, which is derived from QoR-40 and provides an effective assessment of post-operative recovery. It consists of a total of 15-items, grading each recovery item on a 10 - point numerical Likert scale with total QoR-15 score ranging from 0 (extremely poor recovery)to 150 (excellent recovery).

Aim:

The aim of our study is to explore and compare the effects of OFA using dexmedetomidine vs conventional OA on the quality of recovery and perioperative clinical outcomes for all the patients undergoing laparoscopic cholecystectomies, which is one of the most common abdominal general surgical procedures. The hypothesis is that the patients receiving OFA using dexmedetomidine will have better quality of recovery and perioperative outcomes than patients receiving standard OA.

Methods:

This is a prospective, randomized, parallel-group, double-blinded clinical trial that will commence from February 2024 and the recruitment time will be for three to six months at department of Anaesthesia, Dow university hospital (DUH), Dow International medical college (DIMC), Dow university of health sciences (DUHS). The study will be approved by the DUHS institutional review board (IRB). The participants of the study will be invited once they receive full trial information from the surgeons or the anaesthetists during their pre-assessment visits. The study participants will join only for up to one day after the surgery (Post-operative day-1).

Intervention:

Before the study commences the participants will be taught to measure their pain status via visual analog scale (VAS; where 0 cm = no pain and 10 cm = worst pain), with 'sad' or 'happy' pictures at each end. The participants will be advised to ask for analgesia proactively, once the VAS pain score is \>4. All the eligible patients will undergo general anaesthesia for their elective surgeries. In the operating theatre the standard of monitoring will include body temperature, ECG, non-invasive blood pressure, pulse oximetry, neuromuscular monitoring using train-of-four (TOF) stimulation and bispectral index (BIS) for measuring the depth of anaesthesia.

The induction and maintenance of anaesthesia for both OFA vs OA treatment groups will be administered. Once the surgery is completed and after extubation and emergence from anaesthesia, all the participants will be transferred to PACU from where they will be in turn discharged to the ward once they will fulfil the recovery discharge criteria. A multi-modal analgesia regimen along with a prophylactic antiemetic medication is prescribed postoperatively in the ward according to the standard protocol of the department.

For each participant, the mean and total QoR-15 scores will be computed pre-operatively (at baseline) and at24 h (+/- 2 hours) post-operatively. The mean change of QoR-15 scores will be evaluated to establish the difference between the baseline and post-operative day-1 scores. In addition to that the secondary perioperative clinical outcomes will also be recorded in PACU and at 24 hrs postoperatively.

Randomisation:

The participants will be randomized in a 1:1 ratio, using computer-generated random numbers to receive either a standard opioid-based (OA) or opioid-free anaesthesia (OFA) treatment protocols. After obtaining consent, the participants will be assigned a study identification number (ID).

Blinding:

Just before surgery, a concealed envelope containing the study ID will be opened by the anaesthetist, which contains the random allocation of OA or OFA treatment protocols. The participants will be blinded with the treatment groups during the whole study period. The staff members including the recovery and ward nurses providing postoperative care and assessing outcomes in the PACU and the ward will also be kept blinded of the study groups. The anaesthetist administering general anaesthesia could not be blinded due to pragmatic reasons but will not contribute to the care or outcomes assessments during the post-operative period.

Sample size:

According to a previous study the minimal clinically significant mean change of QoR-15 scores is 'eight'. A sample size of 18 participants is required to detect a mean change QoR-15 scores of 'six' with a standard deviation of four and achieve a power of 80% with type-1error of 0.05. A maximum of 15% increase in the number of participants will be added to compensate the loss of the participants due to cancellations or follow-up losses. Therefore, the sample size will include 42 participants (n=21 OFA and n=21 OA).

Statistical Analysis:

All participants randomized will be incorporated in the analyses on an intention-to-treat basis. The Kolmogorov-Smirnov test will be used to assess the distribution of the quantitative variables. For continuous data: mean ± standard deviation, median (IQR), and for categorical data: frequencies or percentages will be measured. Mean and total QoR-15 scores will be calculated for each participant at baseline and on postoperative day-1. To find out the difference between postoperative day-1 and baseline score, a change of QoR-15 change scores will be documented. Quantitative variables will be analysed using an Independent-sample t-test or Mann-Whitney U-test and Chi-square or Fisher's exact test will be applied to investigate the qualitative variables.

To adjust for the effect of baseline preoperative scores, ANCOVA (Analysis of Covariance) will be used to study the relationship between QOR-15 and one or more independent variables. A two tailed p value of \<0.05 will be considered significant. All statistical analysis will be performed using Stata/IC for Mac Version 16.1 (StataCorp, College Station, TX, USA).

Study Timeline

• Study First Submitted: 2024-05-23
• Study First Submitted QC: 2024-06-23
• Study First Posted: 2024-06-26
• Study Start: 2024-07-01
• Primary Completion: 2024-10-15
• Study Completion: 2024-10-31
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-01
• Last Update Posted: 2025-02-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

1. Signed informed consent from the participant.
2. All patients who are aged between 18 - 65 years.
3. American Society of Anaesthesiologists (ASA) classification of I and II
4. Elective Laparoscopic cholecystectomies.

Exclusion Criteria

1. American Society of Anaesthesiologists (ASA) classification of III and above
2. Non-elective surgery
3. Body Mass Index > 35
4. Patients with regular prescription of Beta-blockers
5. Pregnant or breastfeeding women
6. Allergy to Opioids and/or other drugs used in the trial.
7. Chronic use of opioids or benzodiazepines
8. Chronic pain patients
9. Patients with cardiovascular, renal, hepatic or central nervous system diseases
10. Patients with psychiatric illness

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Opioid-free Anaesthesia	Dexmedetomidine injection	-
Opioid-based Anaesthesia	Nalbuphine Injection	-

Primary Outcome Measures

Name	Time	Method
Mean total Quality of recovery (QoR-15) scores.	At 24 hours postoperatively	The QoR-15 is a validated patient reported outcome measure (PROM), which provides an effective assessment of post-operative recovery. It consists of a total of 15-items, grading each recovery item on a 10 - point numerical Likert scale with total QoR-15 score ranging from 0 (extremely poor recovery) to 150 (excellent recovery)

Secondary Outcome Measures

Name	Time	Method
Intraoperative haemodynamic stability	Measured from start to end of anaesthesia	Hypotension (SBP \<80 mmHg or MAP \<60 mmHg)
Anaesthesia and recovery clinical outcomes	Measured at start of anaesthesia till discharge from hospital	Oral Morphine Equivalent Daily Dose (OMEDD)

Trial Locations

Locations (1)

Dow university hospital, Dow university of health sciences; 🇵🇰 Karachi, Sind, Pakistan